Subscribe To
Nextech ar solutions launches public version of aritize 3d saas for ecommerce
Nextech AR Solutions Corp. (CSE:NTAR, OTCQB:NEXCF, neo:NTAR) announced it has launched its ARitize 3D S...
January 20, 2022, 8:58 am
Nextech ar solutions launches public version of aritize 3d saas for ecommerce
Nextech AR Solutions Corp. (CSE:NTAR, OTCQB:NEXCF, neo:NTAR) announced it has launched its ARitize 3D S...
January 20, 2022, 8:58 am
Cardiovascular systems, orbusneich scores fda approval for scoreflex scoring balloon
Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex N...
January 20, 2022, 8:51 am
Cardiovascular systems, orbusneich scores fda approval for scoreflex scoring balloon
Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex N...
January 20, 2022, 8:51 am
Cardiovascular systems, orbusneich scores fda approval for scoreflex scoring balloon
Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex N...
January 20, 2022, 8:51 am
Royalty pharma to announce fourth-quarter and full-year 2021 financial results on february 15, 2022
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 202...
January 20, 2022, 7:45 am
Royalty pharma to announce fourth-quarter and full-year 2021 financial results on february 15, 2022
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 202...
January 20, 2022, 7:45 am
Royalty pharma to announce fourth-quarter and full-year 2021 financial results on february 15, 2022
NEW YORK, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth-quarter and full-year 202...
January 20, 2022, 7:45 am
U.s. xpress enterprises, inc. announces fourth quarter and full year 2021 earnings release date
CHATTANOOGA, Tenn.--(BUSINESS WIRE)--U.S. Xpress Enterprises, Inc. (NYSE: USX) today announced that it will release its fourth quarter and full year 2...
January 19, 2022, 4:15 pm
U.s. xpress enterprises, inc. announces fourth quarter and full year 2021 earnings release date
CHATTANOOGA, Tenn.--(BUSINESS WIRE)--U.S. Xpress Enterprises, Inc. (NYSE: USX) today announced that it will release its fourth quarter and full year 2...
January 19, 2022, 4:15 pm
U.s. xpress enterprises, inc. announces fourth quarter and full year 2021 earnings release date
CHATTANOOGA, Tenn.--(BUSINESS WIRE)--U.S. Xpress Enterprises, Inc. (NYSE: USX) today announced that it will release its fourth quarter and full year 2...
January 19, 2022, 4:15 pm
Polarityte (pte) gets fda nod to begin pivotal ulcer study
PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cuta...
January 19, 2022, 1:05 pm
Polarityte (pte) gets fda nod to begin pivotal ulcer study
PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cuta...
January 19, 2022, 1:05 pm
Polarityte (pte) gets fda nod to begin pivotal ulcer study
PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cuta...
January 19, 2022, 1:05 pm
Why chemocentryx shares are rising
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVneo...
January 19, 2022, 11:29 am
Why chemocentryx shares are rising
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVneo...
January 19, 2022, 11:29 am
Why chemocentryx shares are rising
ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVneo...
January 19, 2022, 11:29 am
Cvrx: the path to 7x investment returns
BaroStim neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market...
January 7, 2022, 1:18 pm
Cvrx: the path to 7x investment returns
BaroStim neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market...
January 7, 2022, 1:18 pm
Cvrx: the path to 7x investment returns
BaroStim neo is the only FDA-approved treatment in its space, leading to 0 competition in a $3bn market...
January 7, 2022, 1:18 pm